- Home
- ALXO vs AIRG Comparison
ALXO vs AIRG Comparison
Compare ALXO & AIRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- AIRG
- Stock Information
- Founded
- ALXO 2015
- AIRG 1995
- Country
- ALXO United States
- AIRG United States
- Employees
- ALXO N/A
- AIRG N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- AIRG Radio And Television Broadcasting And Communications Equipment
- Sector
- ALXO Health Care
- AIRG Technology
- Exchange
- ALXO Nasdaq
- AIRG Nasdaq
- Market Cap
- ALXO 76.5M
- AIRG 79.4M
- IPO Year
- ALXO 2020
- AIRG 2016
- Fundamental
- Price
- ALXO $1.12
- AIRG $6.53
- Analyst Decision
- ALXO Buy
- AIRG Strong Buy
- Analyst Count
- ALXO 6
- AIRG 2
- Target Price
- ALXO $6.64
- AIRG $11.75
- AVG Volume (30 Days)
- ALXO 769.2K
- AIRG 24.7K
- Earning Date
- ALXO 03-06-2025
- AIRG 02-27-2025
- Dividend Yield
- ALXO N/A
- AIRG N/A
- EPS Growth
- ALXO N/A
- AIRG N/A
- EPS
- ALXO N/A
- AIRG N/A
- Revenue
- ALXO N/A
- AIRG $55,586,000.00
- Revenue This Year
- ALXO N/A
- AIRG $13.03
- Revenue Next Year
- ALXO N/A
- AIRG $12.35
- P/E Ratio
- ALXO N/A
- AIRG N/A
- Revenue Growth
- ALXO N/A
- AIRG N/A
- 52 Week Low
- ALXO $0.96
- AIRG $3.71
- 52 Week High
- ALXO $17.83
- AIRG $10.34
- Technical
- Relative Strength Index (RSI)
- ALXO 38.53
- AIRG 39.45
- Support Level
- ALXO $1.00
- AIRG $6.85
- Resistance Level
- ALXO $1.22
- AIRG $7.40
- Average True Range (ATR)
- ALXO 0.09
- AIRG 0.34
- MACD
- ALXO 0.00
- AIRG -0.03
- Stochastic Oscillator
- ALXO 35.12
- AIRG 5.46
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About AIRG Airgain Inc.
Airgain Inc is engaged in providing antenna technologies. These technologies can be used to enable performance wireless networking across devices and markets which include connected homes, enterprises, automotive, and the Internet of Things. It also provides solutions to complex radio frequency, engineering challenges, and improving wireless service that require higher throughput, broad coverage footprint, and carrier-grade quality. Geographically, it derives maximum revenue from North America and also has a presence in China and the Rest of the World. The company products include Antenna Plus: Fleet, M2M, IoT Antennas, Carrier-Class Antenna, Embedded Antennas, and External Dipole Antennas.